দেশ: সিঙ্গাপুর
ভাষা: ইংরেজি
সূত্র: HSA (Health Sciences Authority)
(MenA Lyo) Meningococcal Group A oligosaccharide conjugated to CRM197 protein; (MenCWY) Meningococcal Group C oligosaccharide conjugated to CRM197 protein; (MenCWY) Meningococcal Group W-135 oligosaccharide conjugated to CRM197 protein; (MenCWY) Meningococcal Group Y oligosaccharide conjugated to CRM197 protein
GLAXOSMITHKLINE PTE LTD
J07AH08
10 microgram conjugated to 16.7-33.3 microgram
INJECTION, POWDER, FOR SOLUTION
(MenA Lyo) Meningococcal Group A oligosaccharide conjugated to CRM197 protein 10 microgram conjugated to 16.7-33.3 microgram; (MenCWY) Meningococcal Group C oligosaccharide conjugated to CRM197 protein 5 microgram conjudated to 7.1-12.5 microgram; (MenCWY) Meningococcal Group W-135 oligosaccharide conjugated to CRM197 protein 5 microgram conjugated to 3.3-8.3 microgram; (MenCWY) Meningococcal Group Y oligosaccharide conjugated to CRM197 protein 5 microgram conjugated to 5.6-10 microgram
INTRAMUSCULAR
Prescription Only
GSK Vaccines S.r.l. (MenCWY Liquid)
ACTIVE
2012-01-20
1. NAME OF THE MEDICINAL PRODUCT Menveo powder and solution for solution for injection Meningococcal Group A, C, W135 and Y conjugate vaccine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (0.5 ml of the reconstituted vaccine) contains: (Originally contained in the powder) • Meningococcal group A oligosaccharide_ _ 10 micrograms Conjugated to _Corynebacterium diphtheriae_ CRM 197 protein 16.7 to 33.3 micrograms (Originally contained in the solution) • Meningococcal group C oligosaccharide_ _ 5 micrograms Conjugated to _Corynebacterium diphtheriae_ CRM 197 protein 7.1 to 12.5 micrograms • Meningococcal group W135 oligosaccharide_ _ 5 micrograms Conjugated to _Corynebacterium diphtheriae_ CRM 197 protein 3.3 to 8.3 micrograms • Meningococcal group Y oligosaccharide_ _ 5 micrograms Conjugated to _Corynebacterium diphtheriae _CRM 197 protein 5.6 to 10.0 micrograms For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and solution for solution for injection (powder and solution for injection). The powder is a white to off- white cake. The solution is a colourless clear solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Menveo is indicated for active immunization of adolescents (from 11 years of age) and adults at risk of exposure to _Neisseria meningitidis_ groups A, C, W135 and Y, to prevent invasive disease. The use of this vaccine should be in accordance with official recommendations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Adults Menveo should be administered as a single 0.5 ml injection. Paediatric population Menveo is indicated from the age of 11 years and above and should be administered as a single 0.5 ml injection. Elderly There are l সম্পূর্ণ নথি পড়ুন
1. NAME OF THE MEDICINAL PRODUCT Meningococcal Group A, C, W-135 and Y conjugate vaccine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (0.5 ml of the reconstituted vaccine) contains: (Originally contained in the powder) • Meningococcal group A oligosaccharide 10 micrograms Conjugated to _Corynebacterium diphtheriae _CRM 197 protein 16.7 to 33.3 micrograms (Originally contained in the solution) • Meningococcal group C oligosaccharide 5 micrograms Conjugated to _Corynebacterium diphtheriae _CRM 197 protein 7.1 to 12.5 micrograms • Meningococcal group W-135 oligosaccharide 5 micrograms Conjugated to _Corynebacterium diphtheriae _CRM 197 protein 3.3 to 8.3 micrograms • Meningococcal group Y oligosaccharide 5 micrograms Conjugated to _Corynebacterium diphtheriae _CRM 197 protein 5.6 to 10.0 micrograms For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and solution for solution for injection. The powder is a white to off-white cake. The solution is a colourless clear solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Menveo is indicated for active immunization of children (from 2 months of age), adolescents and adults at risk of exposure to _Neisseria meningitidis _groups A, C, W-135 and Y, to prevent invasive disease. The use of this vaccine should be in accordance with official recommendations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Vaccine schedule for children from 2 to 23 months of age Infants initiating vaccination from 2 to 6 months of age First three doses of Menveo, each of 0.5 ml, should be given with an interval of at least 2 months; the fourth dose should be administered during the second year of life (at 12 to 16 months). Alternatively, when Menveo is given as part of a routine infant immunisation programme or according to a national recommendation, a series consisting of three doses, each of 0.5ml, may be given. The first dose should be administered from the age of 2 months, with a second dose 2 months later. The third dose should be adm সম্পূর্ণ নথি পড়ুন